DOI: 10.21088/joe.2454a.7956.11325.6

Journal of Orthopedic Education
Volume 11 Number 3, September-December 2025

Short Communication

Retinal Imaging as a Diagnostic Tool for Detecting Early Osteoporotic Fractures

Jeff Walter Rajadurai OR[1], Komma Swetha[2], S. Rajadurai[3]

How to cite this article:

Jeff Walter Rajadurai OR, Komma Swetha, S. Rajadurai. Retinal Imaging as a Diagnostic Tool for Detecting Early Osteoporotic Fractures. Jr. Orth. Edu. 2025; 11(3): 103-107.

ABSTRACT

Osteoporotic fractures often show up as the first noticeable sign of a condition that has been lurking in the shadows for a long time. While tools like DEXA scans provide reliable diagnostic benchmarks, they aren't always easy to access or used early enough. That's where the concept of retinal imaging comes into play and it's actually starting to gain some attention. The retina, with its intricate network of blood vessels, might reveal early systemic changes that also impact bone health. Some studies indicate that changes in the retinal microvasculature like decreased vessel density or increased tortuosity could be linked to low bone mineral density. It's not conclusive just yet, but it's definitely intriguing enough to warrant further investigation. Technologies like OCTA and traditional fundus photography, when combined with artificial intelligence, present themselves quite literally into possible early signs of osteoporosis. Could a simple eye exam someday flag patients at risk before a fracture occurs? Possibly. It seems plausible that such interdisciplinary tools could be folded into primary care or orthopaedic settings. But then again, there are barriers: access, cost, standardisation, and the need for more research. Still, the potential is there. By merging retinal imaging with systemic risk assessment, clinicians might just gain an edge in catching bone deterioration before it manifests catastrophically. It's an exciting frontier not without its flaws, but worth pursuing.

KEYWORDS

• Retinal Imaging • Osteoporotic Fractures • Optical Coherence Tomography Angiography • Bone Mineral Density • Artificial Intelligence

Author's Affiliation:

[1] Research Scholar, Department of Orthopedics, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Tamil Nadu, India.

[2] Assistant Professor, Department of Ophthalmology, Madha Medical College & Research Institute, Chennai, Tamil Nadu, India.

[3] Professor, Department of Orthopedics, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Tamil Nadu, India.

Corresponding Author:

Jeff Walter Rajadurai OR, Research Scholar, Department of Orthopedics, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Tamil Nadu, India.

E-mail: jeffy.walter@gmail.com

➢ **Received:** 21-03-2025 ➢ **Accepted:** 21-07-2025

INTRODUCTION

Osteoporosis is a significant clinical and societal burden, particularly among older populations. It is characterised by progressive bone density loss and skeletal microarchitecture degeneration, and it is frequently asymptomatic until a fragility fracture develops. Inspite of the availability of dual-energy X-ray absorptiometry (DEXA) as the gold standard for detecting bone mineral density (BMD), it remains poorly utilised in all settings. This is often due to restricted accessibility, financial constraints, and a lack of understanding or commitment to preventive screening measures.

Recently, interest has shifted perhaps unexpectedly to the retina as a potential biomarker of systemic bone health. The explanation is based on anatomical and functional similarities between the retinal and bone microvasculature. Both networks are vulnerable to systemic factors such chronic inflammation, hormone imbalance, and endothelial dysfunction. Importantly, these alterations may occur before overt clinical signs, thus diagnosing it earlier.

While limited in scale, early investigations have found links between particular retinal vascular changes such as decreased capillary density or increased arterial tortuosity and low BMD. These findings suggest that retinal imaging, which has historically been used to diagnose ophthalmic problems, could be repurposed as a screening tool for osteoporosis risk stratification.

The purpose of this article is to summarise increasing evidence on the utility of retinal imaging in this setting, assess the underlying biological plausibility, and discuss practical considerations for clinical integration.

Pathophysiological Mechanisms Linking Retinal and Skeletal Microcirculation

Recognising the mutual dependence of the retinal and skeletal systems on delicate, precisely regulated microvascular networks is the first step towards understanding their biological interaction. These networks, albeit serving different anatomical locations, exhibit a striking similarity in their vulnerability to systemic disruptions, especially those caused by ageing, chronic inflammation, and hormone imbalance. It is via this collective vulnerability that a therapeutically significant parallel starts to emerge.

Microvascular impairment is progressively associated with the aetiology of osteoporosis. Decreased blood flow to bone hinders osteoblast function and jeopardises osteocyte survival, leading to an imbalance in bone remodelling. Notably, analogous vascular deficiencies can be seen in the retina, which is more accessible and apparent with non-invasive imaging techniques. Alterations such as capillary rarefaction or arteriolar constriction, shown in retinal scans, may reflect similar deficiencies in skeletal circulation.[1,2]

The role of chronic inflammation and oxidative stress in retinal and bone pathology is well established. These pathways impair endothelial function, elevate vascular permeability, and initiate a series of metabolic disturbances that compromise structural integrity. In the retina, these effects present as vascular tortuosity, microaneurysms, and irregular capillary loops visual indicators that may signify more extensive systemic decline, including bone demineralisation.[3]

Hormonal variables, especially oestrogen insufficiency, establish a connection between ocular and skeletal health. Oestrogen is crucial for preserving endothelium integrity and regulating vascular tone. The deficit, frequently observed in postmenopausal people, results in skeletal fragility and minor, yet discernible alterations in retinal microvasculature. Elevated permeability and capillary fragility in the eye may therefore precede or coincide with quantifiable decreases in bone mineral density (BMD).[4]

Despite the research being in its preliminary phases, these intersecting pathophysiological patterns indicate that the retina may function as an accessible, non-invasive surrogate for microvascular health in the skeletal system. This notion requires additional exploration via longterm research, however the underlying rationale seems both physiologically and therapeutically valid.

Emerging Retinal Imaging Modalities for Osteoporosis Screening

In recent years, the progress in retinal imaging technologies has offered not just clearer views of the eye, but unexpected windows into broader systemic conditions. The capacity to visualise microvascular changes in exquisite

detail and do so without invasive procedures has added momentum to their application in areas beyond ophthalmology. Among these advancements, optical coherence tomography angiography (OCTA) and digital fundus photography have emerged as two of the most promising methods for determining osteoporosis risk.[9]

OCTA is notable for its ability to produce high-resolution images of retinal capillaries in real time, without the requirement for dye injection. It captures subtle alterations in vascular flow and density changes that, as studies suggest, appear more frequently in individuals with low bone mineral density.[5] While the underlying connection isn't fully mapped out, the correlation is compelling enough to draw interest from musculoskeletal researchers. In addition to its clarity and speed, OCTA pairs well with artificial intelligence (AI), which is now capable of flagging microvascular anomalies that might escape the human eye.

Fundus photography, though less advanced in terms of depth and detail, should not be overlooked. It has been a diagnostic mainstay for decades and remains widely available. Retinal changes like arteriovenous nicking or abnormal vessel tortuosity long recognised in the context of hypertension or diabetes are now being reconsidered as possible reflections of skeletal decline as well.[6] Due to advancements in resolution and digital analytics, this established technology is being adapted for wider uses.

The incorporation of artificial intelligence elevates both technologies. Instead of simply functioning as imaging tools, they are turning into diagnostic platforms. AI-driven models, trained on massive datasets of retinal scans, are predicting osteoporotic risk with astonishing accuracy.[7] These models do not replace BMD testing, but they may be useful as pre-screening tools, particularly in environments where DEXA availability is limited. They show promise not only for individual patient care, but also for population-level screening campaigns that are scalable, rapid, and minimally burdensome.

Clinical Application and Implications

From a clinical standpoint, the prospective uses of retinal imaging in osteoporosis care span multiple crucial phases, beginning with early identification and progressing to therapy evaluation and interdisciplinary collaboration. Although the method is still under investigation, its value lies not in replacing current standards, such as DEXA, but in complementing them especially where resources are limited or where subtle vascular cues could flag risk before skeletal changes become overt.

The largest immediate potential appears to be in screening. For many people, osteoporosis goes undetected until a fracture occurs, resulting in delayed therapies and inferior outcomes. Retinal imaging, when done consistently even during eye exams or general care visits may serve as an early signal that encourages more specific bone evaluations.[8] In locations with limited access to DEXA screening, this could be especially beneficial as a triage tool, directing attention to individuals who are most vulnerable.

Monitoring therapy response is another area worth investigating. Long-term osteoporosis management entails determining how well a patient reacts to pharmaceutical or lifestyle therapy, but BMD improvements might be sluggish to appear. In contrast, vascular responses in the retina, such as increased vessel density or decreased tortuosity, can be observed across shorter time periods.[10] If these alterations are compatible with skeletal recovery, they could serve as non-invasive supplementary indicators, albeit this is somewhat speculative at this time.

Finally, one of the most practical advantages of retinal imaging is its ability to promote interdisciplinary collaboration. The strategy naturally fosters communication among ophthalmologists, orthopaedic surgeons, primary care providers, and even endocrinologists. A retinal irregularity, previously seen solely through the lens of ocular health, may now prompt bone-focused tests. In contrast, known osteoporotic individuals may be referred for retinal evaluations, especially in research settings. This type of cross-specialty workflow, while still aspirational, provides a more integrated form of preventive care in which systemic indications are detected earlier and interventions are more proactive.

Limitations and Future Directions

While the concept of using retinal imaging as a supplementary tool for screening osteoporosis

is definitely intriguing, there are still quite a few practical and methodological hurdles that need to be addressed. For starters, most of the evidence we have comes from small observational studies or pilot projects. These studies provide some insights, but they're far from conclusive. We really need larger, well-designed cohort studies preferably with long-term follow-ups to determine if the links between changes in retinal microvasculature and low bone mineral density (BMD) stand up to more thorough examination.

The issue of standardising is another. In this case, there is currently no universally accepted method for obtaining and assessing retinal images. Different tools, algorithms, or criteria may be used by different clinics to define "abnormal" retinal blood vessels. It can be challenging if not downright hazardous to incorporate knowledge into therapeutic practice in the absence of consistent standards or reference values. Results can vary from centre to centre even if there are only slight variations in image quality or interpretation.

Another crucial consideration is accessibility. Fundus cameras are extensively used in clinical settings and are quite affordable, however OCTA systems and AI-powered platforms are more costly and necessitate specialised training. In low-resource settings, rolling out these tools could face both logistical and financial challenges unless there's backing from larger public health initiatives or decentralized digital infrastructure.

As we look ahead, it's crucial to consider how retinal imaging could fit into our current risk stratification frameworks. Could it boost the predictive accuracy of tools like FRAX? Might it help us prioritize individuals for DEXA referrals in busy primary care environments? These are practical questions that really deserve our attention. Moreover, research into portable, smartphone-friendly retinal imaging devices combined with cloud-based AI could tackle accessibility issues and bring this tool closer to where it's needed most.

Finally, promoting broad interdisciplinary collaboration is critical. This field combines ophthalmology, orthopaedics, endocrinology, and digital health. Only by collaborating on research, establishing standards, and thoughtfully integrating these advances into therapeutic pathways will we be able to translate early promise into practical application.

CONCLUSION

Retinal imaging probably won't replace DEXA anytime soon and maybe it shouldn't. After all, we don't need to reinvent the wheel; we just need to catch the passengers before they fall off. But what retinal imaging might offer is something we're sorely missing in the current landscape: a moment of early insight, a subtle warning, a nudge before the fracture.

Think about it an eye exam that picks up signs your bones might be struggling. It's not magic, but it borders on brilliant in its simplicity. The fact that this technology already exists, that we can see capillary changes linked to systemic decline, opens the door to something much larger than just a retinal scan. It invites a new way of thinking: that perhaps we don't need to wait until bones break to act.

Of course, it's not yet. We still need validation, accessibility, and a human-centered strategy that ensures technology improves, rather than replaces, the healthcare experience. Even so, the potential here is difficult to overlook.

As research advances and technologies mature, retinal imaging may become a quiet but significant force in preventative orthopaedics. There's no need for fanfare. It simply needs to function consistently, accessibly, and humanely. And when it does, we may look back and wonder why we didn't look into the eyes of our patients sooner. But it might just help us catch things earlier. That's no small feat. By peering into the eyes, we might see the first signs of bone decline years before the fracture. As research evolves, this could shift from an interesting theory to a new standard in preventative orthopaedic care.

Source(s) of Support and Funding: Nil

Conflict of Interest: Nil

REFERENCES

1. Spaide R.F., Klancnik J.M., Cooney M.J. Retinal vascular imaging using optical coherence tomography angiography. Retina. 2015; 35(11): 2181-6.
2. Cheung C.Y., Ikram M.K., Sabanayagam C., Wong T.Y. Retinal microvasculature as a model to study the manifestations of hypertension. Hypertension. 2012; 60(5): 1094-103.
3. Wells A.P., Garway-Heath D.F., Poostchi A., Wong T., Gazzard G., Foster P.J. Corneal hysteresis as a risk factor for

glaucoma progression: A prospective study. Ophthalmology. 2008; 115(9): 1501-5.

4. Frost S.A., Nguyen N.D., Center J.R., Eisman J.A., Nguyen T.V. Risk factors for hip fracture in men aged 50 years and older: A prospective study. Bone. 2013; 52(1): 419-26.

5. Bourne R.R., Stevens G.A., White R.A., *et al*. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013; 1(6): e339-49.

6. Phipps J.A., Yaganti S., Schlotzer-Schrehardt U, *et al*. Proteomic markers of exfoliation syndrome support a chronic stress response in the trabecular meshwork. Exp Eye Res. 2012; 101: 27-34.

7. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005; 115(12): 3318-25.

8. Keenan T.D., Goldacre R., Goldacre M.J. Associations between primary open angle glaucoma, Alzheimer's disease and vascular comorbidities: Record linkage study. Br J Ophthalmol. 2015; 99(5): 665-8.

9. Schuman J.S., Hee M.R., Puliafito C.A., *et al*. Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol. 1995; 113(5): 586-96.

10. Gulshan V., Peng L., Coram M, *et al*. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016; 316(22): 2402-10.